BNP-32 (HUMAN) Chemical Properties

Density 

1.52±0.1 g/cm3(Predicted)

RTECS 

EE1534000

storage temp. 

−20°C

form 

powder

color 

White to off-white

Water Solubility 

Soluble in water at 1mg/ml

Sequence

H-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His-OH(Disulfide bridge: Cys10-Cys26)

CAS DataBase Reference

124584-08-3

Safety Information

WGK Germany 

3

MSDS

• Language:English Provider:SigmaAldrich

BNP-32 (HUMAN) Usage And Synthesis

Description

Nesiritide was introduced in the US as a new intravenous treatment for patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. Nesiritide is the first human recombinant form of the potent vasodilatory B-type natriuretic peptide (also known as brain natriuretic peptide), a naturally occurring 32 amino acid peptide with a disulfide-bonded 17 amino acid ring structure. Nesiritide binds to the Atype natriuretic peptide receptor on the surface of endothelial and smooth muscle cells stimulating production of the second messenger cGMP which mediates predominantly vascular smooth muscle cell relaxation. It also facilitates the elimination of sodium and water by the kidney and decreases the secretion of certain hormones, such as adrenalin, angiotensin II, aldosterone and endothelin, which provoke long-term detrimental effects including blood vessel constriction and blood pressure elevation. In clinical trials with heart failure patients, nesidtide dose-dependently reduced pulmonary capillary wedge pressure, right atrial pressure and systemic vascular resistance and increased cardiac index without affecting heart rate. The major adverse effect observed was dose-dependent hypotension. In a phase III comparative trial, nesiritide was found to be superior to iv. nitroglycerine in its haemodynamic effects as well as easier to administer and better tolerated. Nesiritide is cleared by proteolytic cleavage by the enzyme neutral endopeptidase NEP24.11 and by binding to the C-type natriuretic peptide receptor followed by endocytosis and intracellular lysosomal hydrolysis. Since it has a short half-life (18 min), nesiritide is administered as a 21μg/kg bolus infusion followed by a continuous maintenance infusion at 0.011μg/kg/min usually over 24-48 hours.

Originator

Scios (US)

Uses

Brain natriuretic peptide is originally isolated from brain, but is mainly produced in myoendocrine cells of the heart ventricles from which it is released into the circulation. It is involved in blood pressure control and cardiovascular homeostasis.

Uses

Treatment of congestive heart failure (renin-angiotensin system antagonist).

brand name

Natrecor (Biochemie, Austria).

General Description

The gene encoding brain natriuretic peptide-32 (BNP-32) is localized on human chromosome 1p36.22. It is implicated in several biological functions such as diuresis, natriuresis, hypotensive action and inhibition of aldosterone secretion. BNP-32 acts as a potential biomarker of high left ventricular-diastolic pressure in patients with symptomatic left ventricular (LV) dysfunction. Elevated expression of this protein is observed in acute myocardial infarction (AMI) patients.

Biochem/physiol Actions

Brain natriuretic peptide (type B natriuretic peptide) was originally isolated from brain, but is mainly produced in myoendocrine cells of the heart ventricles from which it is released into the circulation. It is involved in blood pressure control and cardiovascular homeostasis.

storage

Store at -20°C

BNP-32 (HUMAN)(124584-08-3)Related Product Information

• Lisinopril Dihydrate
• Nitrendipine
• Enalapril
• Moxonidine
• Nicorandil
• Propafenone
• Milrinone
• Dobutamine hydrochloride
• Glucagon
• Irbesartan
• (S)-Amlodipine
• Vasopressin
• HIRUDIN (54-65) (DESULFATED)
• Ziconotide Polyacetate
• Simendan
• Liraglutide
• Octreotide
• Nesiritide acetate